November 2016
Certain high-cost products to treat skin conditions won’t be covered due to comparable alternatives
As you read in the September Record, Blue Cross Blue Shield of Michigan commercial plans don’t cover select high-cost, FDA-approved drugs for which more cost-effective therapeutic alternatives are available. This is part of an ongoing effort to address the high cost of drugs and provide the best possible value for our members.
Ultravate®-X kits, Ultravate® lotion, Cordran® lotion, flurandrenolide lotion and Locoid® lotion, which are topical products used to treat corticosteroid-responsive skin conditions, have been targeted for exclusion, effective Oct. 7, 2016. Members currently using these drugs can continue to fill prescriptions for them through Dec. 31, 2016.
The following table includes the approximate cost of the targeted drugs and the associated therapeutic alternatives:
Drug names not covered and their costs** |
Covered therapeutic alternatives and their costs** |
Locoid® lotion (hydrocortisone butyrate) |
$1,046 |
Cordran® lotion (flurandrenolide) |
$1,101 |
flurandrenolide lotion |
$990 |
|
betamethasone dipropionate lotion (Diprosone®) |
$47 |
betamethasone valerate lotion (Valisone®) |
$72 |
triamcinolone lotion (Aristocort, Kenalog®) |
$90 |
|
Ultravate® lotion (halobetasol propionate) |
$1,083 |
Ultravate®-X cream kit
(halobetasol + lac-hydrin, OTC) |
$1,083 |
Ultravate®-X ointment kit
(halobetasol + lac-hydrin, OTC) |
$1,083 |
|
augmented betamethasone
dipropionate- cream, ointment, lotion (Diprolene®) |
$75 - $186 |
clobetasol propionate- cream, ointment (Temovate®) |
$459 - $520 |
fluocinonide- cream, ointment (Lidex®,
Lidex-E®) |
$182 - $293 |
halobetasol propionate- cream,
ointment (Ultravate®) |
$191 |
|
**Approximate cost for a 30-day supply based on the average wholesale price.
In some cases, members’ out-of-pocket costs for these brand-name drugs may be lower than their copay due to manufacturer savings cards. However, the high cost of these drugs will be reflected in future premium rates and the overall claims experience for members and plans.
As part of this ongoing initiative, Blue Cross will continue to identify select high-cost drugs and will stop covering them when there are more cost-effective alternatives available for our commercial members.
|